Objectives: This study aimed to develop an artificial intelligence-assisted model for the preoperative prediction of lateral cervical lymph node metastasis (LCLNM) in papillary thyroid carcinoma (PTC) using computed tomography (CT) radiomics, providing a new noninvasive and accurate diagnostic tool for PTC patients with LCLNM. Methods: This retrospective study included 389 confirmed PTC patients, randomly divided into a training set (n = 272) and an internal validation set (n = 117), with an additional 40 patients from another hospital as an external validation set. Patient demographics were evaluated to establish a clinical model. Radiomic features were extracted from preoperative contrast-enhanced CT images (venous phase) for each patient. Feature selection was performed using analysis of variance and the least absolute shrinkage and selection operator algorithm. We employed support vector machine, random forest (RF), logistic regression, and XGBoost algorithms to build CT radiomic models for predicting LCLNM. A radiomics score (Rad-score) was calculated using a radiomic signature-based formula. A combined clinical-radiomic model was then developed. The performance of the combined model was evaluated using the receiver operating characteristic (ROC) curve, calibration curve, and decision curve analysis (DCA). Results: A total of 1724 radiomic features were extracted from each patient’s CT images, with 13 features selected based on nonzero coefficients related to LCLNM. Four clinically relevant factors (age, tumor location, thyroid capsule invasion, and central cervical lymph node metastasis) were significantly associated with LCLNM. Among the algorithms tested, the RF algorithm outperformed the others with five-fold cross-validation on the training set. After integrating the best algorithm with clinical factors, the areas under the ROC curves for the training, internal validation, and external validation sets were 0.910 (95% confidence interval [CI]: 0.729–0.851), 0.876 (95% CI: 0.747–0.911), and 0.821 (95% CI: 0.555–0.802), respectively, with DCA demonstrating the clinical utility of the combined radiomic model. Conclusions: This study successfully established a clinical-CT radiomic combined model for predicting LCLNM, which may significantly enhance surgical decision-making for lateral cervical lymph node dissection in patients with PTC.
Background: Triple-negative breast cancer (TNBC) is exceptionally aggressive, with a high recurrence rate, resistance to chemotherapy, and a tendency to metastasize. The long non-coding RNA growth arrest-specific 5 (GAS5) is associated with TNBC progression; however, the specific mechanism still requires further exploration. Methods: Integrative bioinformatics analyses and qRT-PCR were used to investigate the significant downregulation of GAS5 in TNBC cells and tissues. The functional role and molecular mechanism of GAS5 in inhibiting the progression of TNBC and increasing sensitivity to chemotherapy were investigated using in vitro experiments, including qPCR, Western blot, CCK8 assay, Transwell, Chemotaxis assays, RNA immunoprecipitation, m6A-RNA immunoprecipitation, Chromatin immunoprecipitation, Flow cytometry, ELISA, and Luciferase reporter assays, and in vivo experiments using tumor xenografts. Results: GAS5 was significantly downregulated in TNBC cells and tissues, as well as in chemotherapy-resistant conditions. Functional assays revealed that overexpression of GAS5 attenuated the progression of TNBC and increased their sensitivity to docetaxel (DTX) both in vitro and in vivo. Furthermore, we confirmed that GAS5 recruited YTHDF2 to target MYBL2, which in turn downregulated the chemokine CCL2, which reduced the recruitment of myeloid-derived immunosuppressive cells (MDSCs). In addition, IL-6 from MDSCs downregulated GAS5 to promote TNBC growth and attenuate the sensitivity of TNBC to DTX through the STAT3/UPF1 axis, forming a feedback loop between tumor cells and MDSCs. Conclusions: These findings illustrated the significance of the GAS5-mediated mutual regulatory pathway between tumor cells and MDSCs in TNBC and provide new avenues for the development of targeted therapies in TNBC.
Background: The objective of this study was to verify that a strategy involving prophylactic exposure of the inferior parathyroid glands and preservation of their venous blood flow—achieved through early identification and protection of their venous drainage—can enhance the success rate of maintaining glandular perfusion and effectively reduce the incidence of postoperative hypoparathyroidism. Methods: This study included 600 patients who underwent total thyroidectomy with concomitant bilateral central neck dissection between November 2019 and December 2025. Patients were divided into two groups based on the surgical technique: Group A ( n = 244), in which a prophylactic approach was used to protect the venous drainage of the inferior parathyroid glands, and Group B ( n = 356), which underwent conventional in situ preservation of the inferior parathyroid glands. A comparison was made between the two groups regarding both the percentage of inferior parathyroid glands successfully preserved in situ and the incidence of postoperative hypoparathyroidism. Results: The rate of visualization of inferior parathyroid glands with optimal blood supply was significantly higher in Group A than in Group B ( p < 0.001). Postoperation parathyroid hormone level in Group A was significantly higher than that in Group B (25.15 [19.39, 33.58] pg/mL vs. 19.12 [9.82, 28.85] pg/mL, p < 0.001). In Group A, the rates of postoperative hypoparathyroidism—encompassing both transient and permanent forms—were significantly lower than those in Group B ( p < 0.001). Conclusions: The method of prophylactically exposing the inferior parathyroid glands and preserving their venous system—termed prophylactic preservation of inferior parathyroid venous blood flow—is achieved through early identification and protection of their venous drainage. This approach enhances the success rate of maintaining glandular blood supply and effectively reduces the incidence of postoperative hypoparathyroidism.